Abstract: 【Abstract】Objective To investigate the clinical efficacy and complications of percutaneous coronary intervention(PCI) in maintenance hemodialysis (MHD) patients with acute coronary syndrome(ACS). Methods A total of 101 MHD patients with ACS treated in Beijing Jishuitan Hospital from July 2014 to April 2019 were enrolled in this study. They were divided into the PCI group(n=32) and the control group(n=69) based on the acceptance of PCI by the patients. Clinical characteristics, changes of kidney function, residual urine volume, left ventricular ejection fraction(LVEF), bleeding events, cardiovascular complications and mortality were compared between the two groups after the treatment for 3 months. Results ①The mean age of the study population was 67.62±12.39 years. There were no statistical differences between the two groups in gender( χ2= 2.889, P= 0.089), age (t=-0.775,P=0.440), dialysis age (t=-0.537,P=0.592), basal residual urine volume (Z=-0.856,P=0.392), basal LVEF value (t=1.781, P=0.078), serum creatinine (Z=-1.522,P=0.128). ②After the treatment for 3 months, there were no statistical differences between the two groups in serum creatinine (Z=-1.306,P=0.191) and residual urine volume (Z= -1.226, P=0.220), but LVEF value was higher in the PCI group than in the control group (Z= -4.229, P＜0.001). ③These patients were followed up to July 2019 and found that there were no statistical differences between the two groups in bleeding events (χ2= 0.155,P=0.694) and recurrence of cardiovascular events (χ2=1.672,P=0.196), but survival period was significantly longer in the PCI group than in the control group (χ2=4.657,P=0.031). Conclusion For MHD patients with ACS, PCI treatment can improve LVEF value and the survival period without the increase of bleeding events and recurrence of cardiovascular events and the impact on residual renal function.

Key words: Maintenance hemodialysis, Acute coronary syndrome, Percutaneous coronary intervention